{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:53:18Z","timestamp":1781639598482,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Dual-phase amyloid PET enables concurrent assessment of amyloid burden and cerebral perfusion, providing both molecular and functional information within a single visit. While amyloid PET is well validated diagnostically, the prognostic value of early-phase perfusion remains less explored. We aimed to determine whether perfusion in Alzheimer\u2019s disease (AD)\u2013relevant regions is associated with longitudinal cognitive trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 218 participants from a memory-clinic cohort ranging from cognitively unimpaired (CU, n\u2009=\u200965) to mild cognitive impairment (MCI, n\u2009=\u2009115) and dementia (n\u2009=\u200938). Based on visual read of late-phase amyloid PET, 123 participants were classified as amyloid-positive (A\u03b2+) and 93 as amyloid-negative (A\u03b2\u2013). The groups differed significantly in age, education, and baseline MMSE (all p\u2009&lt;\u20090.01), but not in sex distribution. Early-phase perfusion was quantified as standardized uptake value ratios (SUVr) within an AD meta\u2013region of interest (posterior cingulate, angular, and temporal cortex) and analyzed using linear mixed-effects models adjusting for age, sex, education, APOE \u03b54 genotype, and white matter lesion burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among A\u03b2+ participants, 11 were CU, 79 MCI, and 33 dementia; among A\u03b2\u2013 participants, 53 were CU, 35 MCI, and 5 dementia. Perfusion declined progressively across clinical stages (CU\u2009&gt;\u2009MCI\u2009&gt;\u2009dementia) and was positively correlated with baseline MMSE (r\u2009=\u20090.39, p\u2009&lt;\u20090.001). In A\u03b2+ individuals, higher baseline perfusion predicted slower MMSE decline over time (interaction \u03b2\u2009=\u20095.85, p\u2009&lt;\u20090.001), whereas no such association was observed in the A\u03b2\u2013 group. No significant association was observed in amyloid-negative participants. These effects remained significant after adjustment for vascular and genetic covariates and were independent of amyloid plaque burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Perfusion derived from early-phase amyloid PET in AD-related regions is a reliable marker of cognitive status and progression in individuals with confirmed amyloid pathology. These findings highlight the added value of dual-phase PET as a practical, single-visit approach for combined diagnostic and prognostic evaluation, particularly where additional functional imaging is not feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07694-1","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T01:42:13Z","timestamp":1772415733000},"page":"4037-4049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3390-8530","authenticated-orcid":false,"given":"A.","family":"\u0160korvagov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-4472","authenticated-orcid":false,"given":"F.","family":"Ribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1135-6865","authenticated-orcid":false,"given":"J.","family":"Cerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5914-5398","authenticated-orcid":false,"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-5129","authenticated-orcid":false,"given":"M.","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9497-0707","authenticated-orcid":false,"given":"A. J","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2982-0188","authenticated-orcid":false,"given":"C.","family":"Wyss-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"V.","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-7082","authenticated-orcid":false,"given":"G.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-4790","authenticated-orcid":false,"given":"R.","family":"Andel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-436X","authenticated-orcid":false,"given":"C.","family":"Boccalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-3726","authenticated-orcid":false,"given":"J.","family":"Hort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"7694_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347. https:\/\/doi.org\/10.1212\/WNL.0000000000002923.","journal-title":"Neurology"},{"key":"7694_CR2","doi-asserted-by":"publisher","unstructured":"Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","DOI":"10.1002\/alz.13859"},{"key":"7694_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, et al. Update on hypothetical model of Alzheimer\u2019s disease biomarkers. Lancet Neurol. 2013;12:207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"Lancet Neurol"},{"key":"7694_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-022-00928-5","volume":"12","author":"E Rauhala","year":"2022","unstructured":"Rauhala E, Johansson J, Karrasch M, et al. Change in brain amyloid load and cognition in patients with amnestic mild cognitive impairment: a 3-year follow-up study. EJNMMI Res. 2022;12:55. https:\/\/doi.org\/10.1186\/s13550-022-00928-5.","journal-title":"EJNMMI Res"},{"key":"7694_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2967\/jnumed.122.264256","volume":"64","author":"C Boccalini","year":"2023","unstructured":"Boccalini C, Peretti DE, Ribaldi F, et al. Early-phase 18F-florbetapir and 18F-flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2023;64:266\u201373. https:\/\/doi.org\/10.2967\/jnumed.122.264256.","journal-title":"J Nucl Med"},{"key":"7694_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102750","volume":"31","author":"M Vanhoutte","year":"2021","unstructured":"Vanhoutte M, Landeau B, Sherif S, et al. Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer\u2019s clinical syndrome. Neuroimage Clin. 2021;31:102750. https:\/\/doi.org\/10.1016\/j.nicl.2021.102750.","journal-title":"Neuroimage Clin"},{"key":"7694_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/nimg.2002.1208","volume":"17","author":"K Herholz","year":"2002","unstructured":"Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302\u201316. https:\/\/doi.org\/10.1006\/nimg.2002.1208.","journal-title":"Neuroimage"},{"key":"7694_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","volume":"36","author":"L Mosconi","year":"2009","unstructured":"Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2009;36:811\u201322. https:\/\/doi.org\/10.1007\/s00259-008-1039-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7694_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.074641","volume":"19","author":"C Boccalini","year":"2023","unstructured":"Boccalini C, Mathoux G, Peretti DE, et al. Defining tau pathology and neurodegeneration by dual-phase 18F-flortaucipir PET as diagnostic and prognostic biomarkers in a memory clinic setting. Alzheimer\u2019s & Dementia. 2023;19:e074641. https:\/\/doi.org\/10.1002\/alz.074641.","journal-title":"Alzheimer's & Dementia"},{"key":"7694_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"key":"7694_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.110.083683","volume":"52","author":"PT Meyer","year":"2011","unstructured":"Meyer PT, Hellwig S, Amtage F, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393\u2013400. https:\/\/doi.org\/10.2967\/jnumed.110.083683.","journal-title":"J Nucl Med"},{"key":"7694_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211000","volume":"14","author":"DE Peretti","year":"2019","unstructured":"Peretti DE, Garc\u00eda DV, Reesink FE, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer\u2019s disease PET studies. PLoS One. 2019;14:e0211000. https:\/\/doi.org\/10.1371\/journal.pone.0211000.","journal-title":"PLoS One"},{"key":"7694_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","volume":"43","author":"S Tiepolt","year":"2016","unstructured":"Tiepolt S, Hesse S, Patt M, et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43:1700\u20139. https:\/\/doi.org\/10.1007\/s00259-016-3353-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7694_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102773","volume":"31","author":"H-J Yoon","year":"2021","unstructured":"Yoon H-J, Kim BS, Jeong JH, et al. Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer\u2019s disease. NeuroImage: Clinical. 2021;31:102773. https:\/\/doi.org\/10.1016\/j.nicl.2021.102773.","journal-title":"NeuroImage: Clinical"},{"key":"7694_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"K Kisler","year":"2017","unstructured":"Kisler K, Nelson AR, Montagne A, et al. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18:419\u201334. https:\/\/doi.org\/10.1038\/nrn.2017.48.","journal-title":"Nat Rev Neurosci"},{"key":"7694_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07175-5","author":"F V\u00f6lter","year":"2025","unstructured":"V\u00f6lter F, Eckenweber S, Scheifele M, et al. Correlation of early-phase \u03b2-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07175-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7694_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00846-z","volume":"13","author":"F Ribaldi","year":"2021","unstructured":"Ribaldi F, Chicherio C, Altomare D, et al. Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimers Res Ther. 2021;13:105. https:\/\/doi.org\/10.1186\/s13195-021-00846-z.","journal-title":"Alzheimers Res Ther"},{"key":"7694_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"7694_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"7694_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01388.x.","journal-title":"J Intern Med"},{"key":"7694_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.str.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318\u201322. https:\/\/doi.org\/10.1161\/01.str.32.6.1318.","journal-title":"Stroke"},{"key":"7694_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-021-00123-0","volume":"6","author":"A Myoraku","year":"2022","unstructured":"Myoraku A, Klein G, Landau S, et al. Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. Eur J Hybrid Imaging. 2022;6:2. https:\/\/doi.org\/10.1186\/s41824-021-00123-0.","journal-title":"Eur J Hybrid Imaging"},{"key":"7694_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","volume":"14","author":"S Daerr","year":"2016","unstructured":"Daerr S, Brendel M, Zach C, et al. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. NeuroImage Clin. 2016;14:77\u201386. https:\/\/doi.org\/10.1016\/j.nicl.2016.10.005.","journal-title":"NeuroImage Clin"},{"key":"7694_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207\u201318. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.07.002.","journal-title":"Neurobiol Aging"},{"key":"7694_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. <article-title update=\"added\">NIA\u2010AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"7694_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915\u201324. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1424.","journal-title":"JAMA Neurol"},{"key":"7694_CR27","first-page":"1778","volume":"47","author":"L Mosconi","year":"2006","unstructured":"Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer\u2019s disease. J Nucl Med Off Publ Soc Nucl Med. 2006;47:1778\u201386.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7694_CR28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","volume":"40","author":"TN Tombaugh","year":"1992","unstructured":"Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922\u201335. https:\/\/doi.org\/10.1111\/j.1532-5415.1992.tb01992.x.","journal-title":"J Am Geriatr Soc"},{"key":"7694_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/BEN-1993-6405","volume":"6","author":"L Sabe","year":"1993","unstructured":"Sabe L, Jason L, Juejati M, et al. Sensitivity and specificity of the Mini-Mental State Exam in the diagnosis of dementia. Behav Neurol. 1993;6:207\u201310. https:\/\/doi.org\/10.3233\/BEN-1993-6405.","journal-title":"Behav Neurol"},{"key":"7694_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"key":"7694_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. The Journal of Prevention of Alzheimer\u2019s Disease. 2023;10:362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"key":"7694_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE, et al. Donanemab: appropriate use recommendations. The Journal of Prevention of Alzheimer\u2019s Disease. 2025;12:100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150.","journal-title":"The Journal of Prevention of Alzheimer's Disease"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07694-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:07:36Z","timestamp":1781636856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07694-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7694"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07694-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. Approval was granted by the Cantonal Commission for Research Ethics (CCER) of Geneva, Switzerland (Reference numbers: 2020\u201300403 and PB_2016\u201301346).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants or their legally authorized representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of anonymized data included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"VG received research support and speaker fees through her institution from GE Healthcare, Siemens Healthineers, Novo Nordisk, Janssen and Novartis.GBF has received unrestricted grants and support for event organization from Roche Pharmaceuticals; OM Pharma; Eisai Pharmaceuticals; Vifor Pharma; Biogen Pharmaceuticals; Novo Nordisk; GE Healthcare; Eli Lilly.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}